Cardiomyopathy clinical trials at UC Irvine

7 in progress, 3 open to eligible people

Showing trials for

  • Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

    open to eligible females ages 18 years and up

    The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.

    Orange, California and other locations

  • CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

    open to eligible people ages 18 years and up

    This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

    Orange, California and other locations

  • TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

    open to eligible people ages 18-85

    The purpose of this study is to: - Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events - Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death - Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life

    Laguna Hills, California and other locations

  • AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

    Sorry, currently not accepting new patients, but might later

    Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

    Orange, California and other locations

  • ALXN2220 Versus Placebo in Adults With ATTR-CM

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

    Irvine, California and other locations

  • AT-001 in Patients With Diabetic Cardiomyopathy

    Sorry, in progress, not accepting new patients

    This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.

    Orange, California and other locations

  • Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

    Sorry, in progress, not accepting new patients

    This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age >18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1

    Irvine, California and other locations

Our lead scientists for Cardiomyopathy research studies include .

Last updated: